Загрузка...
Outcomes of Tofacitinib Dose Reduction in Patients with Ulcerative Colitis in Stable Remission from the Randomised RIVETING Trial
BACKGROUND AND AIMS: Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis. We present primary completion analysis from RIVETING, an ongoing, double-blind, randomised, parallel-group trial evaluating efficacy and safety of tofacitinib dose reduction to...
Сохранить в:
| Опубликовано в: : | J Crohns Colitis |
|---|---|
| Главные авторы: | , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Oxford University Press
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8256630/ https://ncbi.nlm.nih.gov/pubmed/33290538 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjaa249 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|